Zentalis Pharmaceuticals, Inc.
ZNTL
$3.86
-$0.17-4.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.23% | -13.62% | -90.58% | -26.18% | -49.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.11% | 3.35% | -52.78% | -34.41% | -44.65% |
| Operating Income | -23.11% | -3.35% | 25.28% | 34.41% | 44.65% |
| Income Before Tax | -56.84% | 27.02% | 27.06% | 33.58% | 69.47% |
| Income Tax Expenses | -- | -- | 315.61% | -- | -- |
| Earnings from Continuing Operations | -57.35% | 26.78% | 25.82% | 33.54% | 69.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.35% | 26.78% | 25.82% | 33.54% | 69.56% |
| EBIT | -23.11% | -3.35% | 25.28% | 34.41% | 44.65% |
| EBITDA | -23.23% | -3.68% | 25.10% | 34.31% | 44.62% |
| EPS Basic | -58.83% | 25.31% | 26.23% | 34.48% | 69.96% |
| Normalized Basic EPS | -55.23% | -11.41% | 31.08% | 34.54% | 58.50% |
| EPS Diluted | -58.83% | 25.31% | 26.23% | 34.48% | 69.96% |
| Normalized Diluted EPS | -55.23% | -11.41% | 31.08% | 34.54% | 58.50% |
| Average Basic Shares Outstanding | -0.93% | -1.97% | 0.55% | 1.45% | 1.34% |
| Average Diluted Shares Outstanding | -0.93% | -1.97% | 0.55% | 1.45% | 1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |